Aarhus Universitets segl

Nils Skajaa

Statins and risk of diverticular disease: Nested case-control study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Statins and risk of diverticular disease: Nested case-control study. / Skajaa, Nils; Troelsen, Frederikke Schønfeldt; Pedersen, Lars et al.
I: Pharmacoepidemiology and Drug Safety, Bind 30, Nr. 6, 06.2021, s. 770-778.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

Skajaa, N., Troelsen, F. S., Pedersen, L., Ekholm, O., Strate, L. L., Erichsen, R., & Sørensen, H. T. (2021). Statins and risk of diverticular disease: Nested case-control study. Pharmacoepidemiology and Drug Safety, 30(6), 770-778. adv. onlinepublikation. https://doi.org/10.1002/pds.5205

CBE

MLA

Vancouver

Skajaa N, Troelsen FS, Pedersen L, Ekholm O, Strate LL, Erichsen R et al. Statins and risk of diverticular disease: Nested case-control study. Pharmacoepidemiology and Drug Safety. 2021 jun.;30(6):770-778. Epub 2021 feb. 14. doi: 10.1002/pds.5205

Author

Bibtex

@article{ccbeea6ba86847e7a2a008bbac8e9a74,
title = "Statins and risk of diverticular disease: Nested case-control study",
abstract = "BACKGROUND: Statins exert pleiotropic anti-inflammatory effects and may prevent diverticular disease. However, the association remains poorly understood with previous studies obtaining conflicting results.AIMS: To examine the effect of statin on the subsequent risk of diverticular disease.METHODS: We conducted a nested case-control study in Denmark among respondents (>18 years) of the 2010 or the 2013 Danish National Health Survey. Among these, we identified 8,809 cases of hospital-diagnosed diverticular disease and risk-set sampled population controls without diverticular disease. Using complete prescription and hospital records, we used conditional logistic regression to compute odds ratios (ORs) associating statin use with diverticular disease. In adjusted analyses, we controlled for hospital-based diagnoses, medication use other than statins, and lifestyle and socioeconomic factors.RESULTS: The fully-adjusted OR for diverticular disease associated with ever use (≥1 statin prescription filling) was 1.19 (95% CI: 1.12-1.27) compared with never use. However, we observed no dose-response relation. For example, among short-term users (<5 years), the OR was 1.18 (95% CI: 1.04-1.35) for low intensity users and 1.13 (95% CI: 1.01-1.26) for high intensity users. Among long-term users (≥5 years), the respective ORs were 1.25 (95% CI: 1.13-1.38) and 1.11 (95% CI: 0.98-1.24). In analyses restricting to cases and controls with a previous colonoscopy, associations were null (OR: 1.01 [95% CI: 0.85-1.20]).CONCLUSIONS: The observed association of a higher risk of diverticular disease associated with statins could be explained by diagnostic bias. Our study did not support a protective nor harmful effect of statins on the risk of diverticular disease. This article is protected by copyright. All rights reserved.",
keywords = "diverticular disease, nested case–control study, statins",
author = "Nils Skajaa and Troelsen, {Frederikke Sch{\o}nfeldt} and Lars Pedersen and Ola Ekholm and Strate, {Lisa L} and Rune Erichsen and S{\o}rensen, {Henrik Toft}",
note = "This article is protected by copyright. All rights reserved.",
year = "2021",
month = jun,
doi = "10.1002/pds.5205",
language = "English",
volume = "30",
pages = "770--778",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "JohnWiley & Sons Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - Statins and risk of diverticular disease

T2 - Nested case-control study

AU - Skajaa, Nils

AU - Troelsen, Frederikke Schønfeldt

AU - Pedersen, Lars

AU - Ekholm, Ola

AU - Strate, Lisa L

AU - Erichsen, Rune

AU - Sørensen, Henrik Toft

N1 - This article is protected by copyright. All rights reserved.

PY - 2021/6

Y1 - 2021/6

N2 - BACKGROUND: Statins exert pleiotropic anti-inflammatory effects and may prevent diverticular disease. However, the association remains poorly understood with previous studies obtaining conflicting results.AIMS: To examine the effect of statin on the subsequent risk of diverticular disease.METHODS: We conducted a nested case-control study in Denmark among respondents (>18 years) of the 2010 or the 2013 Danish National Health Survey. Among these, we identified 8,809 cases of hospital-diagnosed diverticular disease and risk-set sampled population controls without diverticular disease. Using complete prescription and hospital records, we used conditional logistic regression to compute odds ratios (ORs) associating statin use with diverticular disease. In adjusted analyses, we controlled for hospital-based diagnoses, medication use other than statins, and lifestyle and socioeconomic factors.RESULTS: The fully-adjusted OR for diverticular disease associated with ever use (≥1 statin prescription filling) was 1.19 (95% CI: 1.12-1.27) compared with never use. However, we observed no dose-response relation. For example, among short-term users (<5 years), the OR was 1.18 (95% CI: 1.04-1.35) for low intensity users and 1.13 (95% CI: 1.01-1.26) for high intensity users. Among long-term users (≥5 years), the respective ORs were 1.25 (95% CI: 1.13-1.38) and 1.11 (95% CI: 0.98-1.24). In analyses restricting to cases and controls with a previous colonoscopy, associations were null (OR: 1.01 [95% CI: 0.85-1.20]).CONCLUSIONS: The observed association of a higher risk of diverticular disease associated with statins could be explained by diagnostic bias. Our study did not support a protective nor harmful effect of statins on the risk of diverticular disease. This article is protected by copyright. All rights reserved.

AB - BACKGROUND: Statins exert pleiotropic anti-inflammatory effects and may prevent diverticular disease. However, the association remains poorly understood with previous studies obtaining conflicting results.AIMS: To examine the effect of statin on the subsequent risk of diverticular disease.METHODS: We conducted a nested case-control study in Denmark among respondents (>18 years) of the 2010 or the 2013 Danish National Health Survey. Among these, we identified 8,809 cases of hospital-diagnosed diverticular disease and risk-set sampled population controls without diverticular disease. Using complete prescription and hospital records, we used conditional logistic regression to compute odds ratios (ORs) associating statin use with diverticular disease. In adjusted analyses, we controlled for hospital-based diagnoses, medication use other than statins, and lifestyle and socioeconomic factors.RESULTS: The fully-adjusted OR for diverticular disease associated with ever use (≥1 statin prescription filling) was 1.19 (95% CI: 1.12-1.27) compared with never use. However, we observed no dose-response relation. For example, among short-term users (<5 years), the OR was 1.18 (95% CI: 1.04-1.35) for low intensity users and 1.13 (95% CI: 1.01-1.26) for high intensity users. Among long-term users (≥5 years), the respective ORs were 1.25 (95% CI: 1.13-1.38) and 1.11 (95% CI: 0.98-1.24). In analyses restricting to cases and controls with a previous colonoscopy, associations were null (OR: 1.01 [95% CI: 0.85-1.20]).CONCLUSIONS: The observed association of a higher risk of diverticular disease associated with statins could be explained by diagnostic bias. Our study did not support a protective nor harmful effect of statins on the risk of diverticular disease. This article is protected by copyright. All rights reserved.

KW - diverticular disease

KW - nested case–control study

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=85101138774&partnerID=8YFLogxK

U2 - 10.1002/pds.5205

DO - 10.1002/pds.5205

M3 - Journal article

C2 - 33583126

VL - 30

SP - 770

EP - 778

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 6

ER -